Maxim Group set a $14.00 target price on Mesoblast Limited (NASDAQ:MESO) in a research report released on Wednesday morning. The firm currently has a buy rating on the stock.

MESO has been the topic of a number of other research reports. Cantor Fitzgerald restated a buy rating on shares of Mesoblast Limited in a research note on Wednesday, August 23rd. Zacks Investment Research lowered Mesoblast Limited from a buy rating to a hold rating in a research note on Wednesday, November 1st. Oppenheimer Holdings, Inc. set a $16.00 price objective on Mesoblast Limited and gave the stock a buy rating in a research note on Tuesday. BidaskClub lowered Mesoblast Limited from a sell rating to a strong sell rating in a research note on Friday, July 28th. Finally, Credit Suisse Group set a $11.00 price objective on Mesoblast Limited and gave the stock a hold rating in a research note on Tuesday, July 18th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. Mesoblast Limited presently has a consensus rating of Hold and a consensus price target of $13.14.

Mesoblast Limited (MESO) traded down $0.09 during trading on Wednesday, reaching $4.91. The company’s stock had a trading volume of 31,798 shares, compared to its average volume of 31,514. Mesoblast Limited has a 12-month low of $4.39 and a 12-month high of $12.50.

WARNING: “Mesoblast Limited (MESO) Given a $14.00 Price Target by Maxim Group Analysts” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/16/mesoblast-limited-meso-given-a-14-00-price-target-by-maxim-group-analysts.html.

Mesoblast Limited Company Profile

Analyst Recommendations for Mesoblast Limited (NASDAQ:MESO)

Receive News & Stock Ratings for Mesoblast Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast Limited and related stocks with our FREE daily email newsletter.